An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2021Yazar
Sevindik, Ömür GökmenÖzkurt, Zübeyde Nur
Boğa, Can
Kalayoğlu Beşışık, Sevgi
İpek, Yıldız
Gedük, Ayfer
Harmandalı, Aybüke
Salihoğlu, Ayşe
Haydaroğlu Şahin, Handan
Sönmez, Mehmet
Vural, Filiz
Akay, Olga Meltem
Kurt Yüksel, Meltem
Maral, Senem
Ekinci, Ömer
Kırkızlar, Hakkı Onur
Tekinalp, Atakan
Demir, Nazlı
Merter, Mustafa
Saydam, Güray
Alacacıoğlu, İnci
Yeğin, Zeynep Arzu
Kasar, Mutlu
Mastanzade, Metban
Özsan, Güner Hayri
Üst veri
Tüm öğe kaydını gösterKünye
Sevindik, Ö. G., Özkurt, Z. N., Boğa, C., Kalayoğlu Beşışık, S., İpek, Y., Gedük, A. ... Özsan, G. H. (2021). An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy. Clinical Lymphoma, Myeloma & Leukemia içinde (S102-S103. ss.).Özet
Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the database of Turkish Myeloma Registry project were included in this study if they had only received one or two lines of therapy. Demographics, patient, and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented.
WoS Q Kategorisi
Q3Kaynak
Clinical Lymphoma, Myeloma & LeukemiaCilt
21Sayı
Supplement:2Koleksiyonlar
- Bildiri Koleksiyonu [515]
- WoS İndeksli Yayınlar Koleksiyonu [6432]